APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness.

@article{CasillasMuoz2018APOA1AA,
  title={APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness.},
  author={Fidel Casillas-Mu{\~n}oz and Yeminia Valle and Jos{\'e} Francisco Mu{\~n}{\'o}z-Valle and Diana Emilia Mart{\'i}nez-Fern{\'a}ndez and Gabriela Lizet Reynoso-Villalpando and H{\'e}ctor Enrique Flores-Salinas and Mara Ana{\'i}s Llamas-Covarrubias and Jorge Ram{\'o}n Padilla-Guti{\'e}rrez},
  journal={Medicina clinica},
  year={2018},
  volume={151 1},
  pages={
          1-7
        }
}
BACKGROUND AND OBJECTIVE Lipid metabolism alterations contribute to acute coronary syndrome (ACS). rs670, rs5070 and rs693 polymorphisms have shown to modify the risk of cardiovascular disease. Apolipoprotein A-I (ApoA-I) plays a major role in reverse cholesterol transport; apolipoprotein B (ApoB) contributes to accumulation of cholesterol in the plaque. The aim of this study was to investigate the association of rs670 and rs5070 polymorphisms of APOA1 and rs693 polymorphism of APOB with ACS… CONTINUE READING
1 Citations
32 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…